Trading was heavy with 145K shares changing hands in the last trading session. Shares saw a steep increase in trading volume of 318.78% over the normal average daily volume.
Traders are more bullish on the company lately if you take into consideration the decrease in short interest. The company experienced a fall in short interest of -5.34% as of the latest report on October 13, 2017. Short interest decreased 22,865 over that timeframe. With short interest at 405,487 and short average daily volume at 32,040, the short-interest ratio is 13.0 and the short interest percentage is 0.03% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (SRDX). As of quarter end D. E. Shaw & CO., Inc. had acquired 9,887 shares growing its stake by 12.0%. The value of the investment in SRDX went from $2,325,000 to $2,866,000 a change of $541,000 since the last quarter. Segall Bryant & Hamill, LLC divested its ownership by shedding 3,056 shares a decrease of 2.3%. Segall Bryant & Hamill, LLC controls 127,565 shares with a value of $3,955,000. The value of the position overall is up by 7.6%.
Disciplined Growth Investors Inc /mn trimmed its position by selling 9,300 shares a decrease of 4.9% from 06/30/2017 to 09/30/2017. Disciplined Growth Investors Inc /mn now holds 181,055 shares worth $5,613,000. The total value of its holdings increased 4.8%. State Street Corp reduced its stake by selling 3,383 shares a decrease of 1.0% as of 09/30/2017. State Street Corp owns 323,114 shares valued at $10,022,000. The value of the position overall is up by 9.1%.
The company is now down by 0.31% since yesterday’s close of 32.15. Surmodics Inc currently has a P/E ratio of 109.59 and market cap is 420.17M. In the last earnings report the EPS was $0.29 with 13.11M shares presently outstanding.
Surmodics, Inc., launched on June 27, 1979, is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Business’s business segments partner with medical device, diagnostic and life science companies to develop and commercialize products designed to improve patient diagnosis and treatment. As of September 30, 2016, the Company had over 150 licensed product classes (customer products utilizing Surmodics technology) in the market generating royalties and over 100 customer product classes incorporating its technology in various stages of pre-commercialization..